BDTX logo

BDTX
Black Diamond Therapeutics Inc

2,675
Mkt Cap
$157.58M
Volume
626,386.00
52W High
$4.94
52W Low
$1.90
PE Ratio
-3.63
BDTX Fundamentals
Price
$2.75
Prev Close
$2.86
Open
$2.82
50D MA
$2.55
Beta
1.96
Avg. Volume
841,419.91
EPS (Annual)
$0.3886
P/B
1.51
Rev/Employee
$3.33M
$30.01
Loading...
Loading...
News
all
press releases
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
Zacks·7d ago
News Placeholder
More News
News Placeholder
Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday
Black Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-black-diamond-therapeutics-inc-stock...
MarketBeat·14d ago
News Placeholder
HC Wainwright Issues Positive Forecast for BDTX Earnings
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright upped their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Wednesday...
MarketBeat·17d ago
News Placeholder
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
Zacks·20d ago
News Placeholder
Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy
Jefferies Financial Group upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a report on Thursday...
MarketBeat·24d ago
News Placeholder
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
Zacks·25d ago
News Placeholder
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.
Zacks·25d ago
News Placeholder
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
Zacks·25d ago
News Placeholder
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1mo ago
News Placeholder
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat reports...
MarketBeat·1mo ago
<
1
2
...
>

Latest BDTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.